Abstract YO40
Case summary
Introduction: Giant cell tumor (GCT) of bone are benign but locally aggressive primary bone tumors.They occur predominantly in long bones of adolescents and young adults typically in the epiphysis. Malignant giant cell tumors of bone (MGCTB) are rare, occurring in less than 1% of GCT of bone. Primary malignant GCT (PMGCT) is a high-grade sarcoma that arises side by side with benign GCTs. Secondary malignant GCT (SMGCT) is a high-grade sarcoma that occurs at the site where a GCTwas previously treated either by radiotherapy (radiation-induced form) or surgery (evolutionary form).
Case Description: A 30 year old female presented with progressive swelling and pain around the left knee for six months without any significant preceding history. X- Ray showed an expansile lytic lesion involving epiphysis of tibia and features suggestive of GCT. She underwent tumor resection and custom made prosthesis replacement. Post op histopathology showedGCT.Six months later the pain and swelling recurred. She was re evaluated with CT left leg which showed recurrent GCT 20x20 cm with soft tissue extension.Biopsy showed malignancy with GCT.Whole body FDG-PET CT was suggestive of tumor recurrence in left proximal tibia with associated soft tissue mass with inguinal nodal and pulmonary metastasis. She received palliative RT 30Gy in 10 fractions.Due to local progression she underwent palliative above knee amputation. Post op histopathology was suggestive of giant cell rich sarcoma.She received 3 cycles of chemotherapy with cisplatin and adriamycin. She expired after 3rd cycle of chemotherapy.
Discussion:PMGCT typically is difficult to distinguish from giant cell tumor of bone, as clinical and radiographic presentation of PMGCT can mimic that of a benign lesion. Malignancies in GCTs are extremely rare events. Since these are aggressive tumors with poor prognosis, it is important that they be recognized at an early stage so that they can be treated adequately by aggressive surgery and chemotherapy.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract